Xynomic Pharmaceuticals Holdings, Inc. announced that the Independent Ethics Committees at three leading Chinese cancer hospitals have approved Xynomic’s application to conduct pivotal Phase 3 trial using the company’s abexinostat, in combination with pazopanib, in patients with renal cell carcinoma. In addition, the Independent Ethics Committees at the Cancer Hospital Chinese Academy of Medical Sciences in Beijing and West China Hospital of Sichuan University have approved Xynomic’s application to conduct two pivotal Phase 2 trials, one to test abexinostat as a third-line mono therapy against diffuse large B-cell lymphoma and the other as a third-line mono therapy against follicular lymphoma. According to Chinese Medical Association’s Chinese Society of Hematology, DLBCL and FL are the most prevalent and second most prevalent non-Hodgkin’s lymphoma subtype, respectively, in China.